Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative

Research and development

Amortization of acquired intangibles

Restructuring - operating expenses

Acquisition related expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

ResMed reports robust Q1 performance, eyes margin expansion and partnerships

ResMed's Q1 2023 performance reflects strong revenue growth and a focus on meeting global demand for connected CPAP and APAP devices. The company faces challenges in maintaining gross margins and managing operating expenses but sees opportunities in expanding margins and engaging with new patient segments.

ResMed reports robust Q2 earnings, eyes growth through innovation

ResMed's Q2 2023 earnings call highlighted strong sales growth, increased revenue, and a focus on innovation.
Challenges in supply chain constraints and operating expenses were noted, alongside opportunities in growth drivers.
The company aims to improve lives through respiratory care solutions and digital health innovations by 2025.
ResMed's performance reflects post-COVID awareness of respiratory health importance and customer acceptance of new devices.

ResMed reports robust Q3 performance, eyes global growth opportunities

ResMed's Q3 earnings call highlighted strong financial performance, growth in device revenue and mask sales, and a focus on sustaining profitable growth. The company aims to address challenges in gross margin decline by leveraging opportunities for expansion and reinvestment in growth.

ResMed reports strong Q4 earnings, eyes international growth opportunities

ResMed's Q4 2023 showcased robust financial performance with revenue and earnings growth.
The company's focus on patient care, innovation, and international expansion presents promising opportunities.
Challenges include managing operating expenses, gross margin decline, and pricing dynamics.
Strategic initiatives to improve gross margins and drive revenue growth position ResMed well for the future.

ResMed reports 16% revenue growth in Q1 2024 earnings call

ResMed's Q1 2024 performance showcased revenue growth driven by strong device and mask sales globally.
Despite challenges like margin decline and increased expenses, the company's strategic focus on core business and innovation remains strong.
Opportunities lie in expanding alternative therapies, sustaining growth in devices and masks, and optimizing the SaaS business.
Overall, ResMed is positioned for accelerated profitable growth, prioritizing cost optimization and key initiatives for future success.

ResMed reports strong Q2 earnings, eyes global healthcare expansion

ResMed's Q2 2024 earnings call showcased robust financial performance, strategic priorities in healthcare innovation, and a focus on delivering value through patient care. Despite challenges, the company remains optimistic about growth potential and stakeholder engagement in its mission.

ResMed reports strong Q3 results, eyes global expansion and innovation

ResMed's Q3 earnings call showcased solid financial performance, operational improvements, and a strategic focus on market expansion. With a strong emphasis on innovation and cost discipline, the company is poised for continued growth despite challenges.

ResMed reports robust Q4 growth, eyes digital health opportunities

ResMed's Q4 performance was strong, driven by robust growth and financial stability.
While facing challenges like medication impact and market expansion, opportunities in digital health and partnerships exist.
The company's focus on patient awareness and demand generation remains key to future growth.
Overall, ResMed's strategic initiatives position it well for continued success and innovation.

ResMed excels in Q1 with strong revenue growth and innovation

ResMed's Q1 performance reflects strong revenue growth, product success, and strategic investments.
The company's strengths lie in innovation, supply chain optimization, and proactive growth strategies.
Challenges include competitive pressures, addressing new patient demand, and balancing acquisitions with operational efficiency.
Opportunities abound in digital health, customer partnerships, and expanding patient care pathways.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ResMed (RMD) reported earnings 30 days ago. What's next for the stock?

Why Is ResMed (RMD) Down 1.7% Since Last Earnings Report?

Investors are optimistic about ResMed's (RMD) increased adoption of AirSense10 and AirSense11 devices.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

ResMed's (RMD) new AirCurve11 series incorporates MyAir and AirView digital health apps to provide maximum comfort and support during therapy.

ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 (Revised)

ResMed's (RMD) new AirCurve11 series incorporates myAir and AirView digital health apps to provide maximum comfort and support during therapy.

ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 Device

Enhances availability of device therapy options, particularly for those who struggle with single pressure PAP therapy Part of Air11 Solutions, key features include Care Check-in, Personal Therapy Assistant, among others to provide support to patients and insights to clinicians and providers when used with AirView and myAir app SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) launched today its AirCurve 11 series devices, the company's newest bilevel devices that use two levels of support, inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP), combined with digital technology to make it easier for healthcare providers to treat sleep apnea and to help patients start and stay on therapy. AirCurve 11 devices are built on ResMed's market-leading AirSense 11 platform and enhance the suite of offerings available for healthcare providers and clinicians when determining the best care for sleep apnea patients.

ResMed's New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea

Realty Income Corp

Oracle

PagSeguro Digital

Petroleo Brasileiro

Polaris

Qualys

Roper Technologies

MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income. Part 7 of this series includes Oracle, Petrobras, Polaris, Realty Income and ResMed, among others.

MoneyShow's Best Investment Ideas For 2024: Part 7

ResMed's (RMD) Q2 results reflect cost discipline to support an acceleration in profitability.

ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand

ResMed topped consensus Wall Street revenue and earnings estimates with its fiscal Q2 results. The company delivered double-digit-percentage growth across all of its products and services.

Why ResMed Stock Is Jumping Today

ResMed reported a strong December-quarter beat, an analyst said Thursday as RMD stock surged, retaking its 200-day moving average.

ResMed Surges But Hits A Ceiling As The Battle With Weight-Loss Drugs Rages

ResMed Inc. (RMD) Q2 2024 Earnings Call Transcript

While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ResMed (RMD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

ResMed (RMD) came out with quarterly earnings of $1.88 per share, beating the Zacks Consensus Estimate of $1.81 per share. This compares to earnings of $1.66 per share a year ago.

ResMed (RMD) Tops Q2 Earnings and Revenue Estimates

ResMed beat Wall Street estimates for second-quarter revenue and profit on Wednesday, powered by strong demand for its respiratory devices used to treat sleep apnea.

ResMed beats estimates on strong sleep apnea device sales

Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024

Takeda Pharmaceutical

Tempur Sealy International

Google “How important is sleep?” and you get three billion results.

3 Stocks to Buy to Benefit From the Booming Sleep Industry

I opine RMD is now attractively valued given its long-term stability and its product is highly demanded. ResMed's product is in high demand in the modern obesity epidemic. A new weight loss drug will have little effect on the Company.

Why ResMed Is One Of My Top Picks In 2024

Evaluate the expected performance of ResMed (RMD) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Stay Ahead of the Game With ResMed (RMD) Q2 Earnings: Wall Street's Insights on Key Metrics

ResMed said its respiratory masks containing magnets will remain on the market even though the U.S. Food and Drug Administration classified a recall of the product as most serious as their use could cause major injuries or death.

ResMed says its masks to remain on market despite FDA classification

The U.S. Food and Drug Administration (FDA) on Thursday classified the recall of certain respiratory masks made by ResMed as most serious as their use could cause major injuries or death.

US FDA identifies recall of ResMed's respiratory devices as most serious

ResMed is a profitable company with steady growth and attractive margins, making it a solid investment opportunity. The company operates mainly in the sleep apnea market, which is expected to grow significantly in the coming years. Despite being down, the stock has rebounded and is expected to continue gaining in the future.

ResMed: A Buy For Investors Seeking Long-Term Rewards

SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2024 on Wednesday, January 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024

SAN DIEGO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer and chair of the board, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, beginning at approximately 2:15 p.m. (Pacific Standard Time) at the Westin St. Francis in San Francisco, CA.

ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference

ResMed's masks with magnets are safe when used in accordance with the updated Instructions for Use ResMed's masks with magnets are safe when used in accordance with the updated Instructions for Use

ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices

SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced that it has secured a significant victory after the United States Patent Trial and Appeals Board (PTAB) invalidated the claims New York University (NYU) asserted against ResMed, based on seven NYU patents. In June 2021, NYU filed a complaint for patent infringement against ResMed in the United States District Court, District of Delaware.

ResMed Secures Significant Victory in Patent Fight Against New York University

Published in the Journal of the American Medical Association Network Open, study estimates  global COPD burden from 2020 through 2050 Study projects disproportionate growth in COPD among women and low-middle income regions SAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the results of a study on the global burden of Chronic Obstructive Pulmonary Disease (COPD) through 2050. Published in the Journal of the American Medical Association (JAMA) Network Open, the study found that COPD prevalence among those 25 years and older is expected to increase by 23% from 2020 to 2050, with the largest growth projected among women and within low- and middle-income countries.

News for ResMed Stock (RMD)